News
Zacks Investment Research on MSN9h
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
Ionis Pharmaceuticals IONS reported second-quarter 2025 adjusted earnings per share (EPS) of 86 cents, significantly beating the Zacks Consensus Estimate of 27 cents. In the year-ago period, the ...
The biopharmaceutical industry is growing rapidly as a result of significant advancements in biotechnology and drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback